Bibliography
- Zhang XS, Xiang BR. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 2009;18:875-85
- About us. Available from: http://www.pharmaprojects.com/about_us/ [Last accessed 22 July 2011]
- Bleeding time study with AZD6482, Clopidogrel and ASA. Available from: http://clinicaltrials.gov/ct2/show/NCT00853450?term=NCT00853450&rank=1 [Last accessed 29 July 2011]
- Study to investigate safety and tolerability of a single dose of AZD6482. Available from: http://clinicaltrials.gov/ct2/show/NCT00688714?term=NCT00688714&rank=1 [Last accessed 29 July 2011]
- Development pipeline. Available from: http://www.astrazeneca-annualreports.com/2010/additional-information/development-pipeline.htm [Last accessed 22 July 2011]
- Eli Lilly and Co. second quarter financial review July 22nd, 2010. Available from: http://lly.client.shareholder.com/common/download/download.cfm?companyid=LLY&fileid=388491&filekey=ecc503d1-ec98-4fbc-ab89-65847d145557&filename=LLY_Q2_Presentation.pdf [Last accessed 22 July 2011]
- Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace 2010;12:1003-10
- Clinical study report synopsis. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D3190C00005 [Last accessed 22 July 2011]
- Clinical study report synopsis. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D3190C00009 [Last accessed 22 July 2011]
- All discontinued products. Available from: http://www.astrazenecaclinicaltrials.com/other-drug-products/discontinued-products/AZD1305/ [Last accessed 22 July 2011]
- Kawasumi H, Satoh N, Kitada Y. Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci 2007;103:222-33
- Bär FW, Tzivoni D, Dirksen MT, Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006;27:2516-23
- Jang IK, Senatore F, Weisman N, A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2007;49(Suppl A):1025-133
- State of new product development. Available from: http://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1003.pdf [Last accessed 22 July 2011]
- Kohrt JT, Bigge CF, Bryant JW, The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007;70:100-12
- Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol 2010;3:227-41
- Squizzato A, Dentali F, Steidl L, New direct thrombin inhibitors. Intern Emerg Med 2009;4:479-84
- Xuan D, Boyd R, DiCarlo L. Population pharmacokinetics of pd 0348292, an oral, direct factor Xa inhibitor, in total knee replacement surgery patients. Clin Pharmacol Ther 2010;87:PII-47
- Cohen AT, Armstrong D, Gazdzik T, An adaptive-design dose-ranging study of PD 0348292, a new oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery [abstract 980]. American Society of Hematology Annual Meeting and Exposition; 2008
- Products under development. Available from: http://www.kyorin-gr.co.jp/en/ir/pdf/ar09/AR2009E12.pdf [Last accessed 22 July 2011]
- Mid-term business plan. Available from: http://www.kyorin-gr.co.jp/en/ir/pdf/20100512hope100.pdf [Last accessed 22 July 2011]
- Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. Available from: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2444&sKey=24cca492-8584-4d65-99e8-c1d717ed3985&cKey=3de2074e-335f-4b0a-a810-8282c0c2fd98&mKey=%7B7A9907EF-0B49-4421-A7AE-7E7F1EBB9402%7D [Last accessed 22 July 2011]
- Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity. Available from: http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml [Last accessed 22 July 2011]
- Safety and efficacy of LCI699 in Cushing's disease patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01331239?term=NCT01331239&rank=1 [Last accessed 29 July 2011]
- Form 20-F GlaxoSmithKline plc. Available from: http://www.gsk.com/investors/reps04/20F-2004.pdf [Last accessed 29 July 2011]
- A clinical study assessing the potential of Piboserod for the treatment of heart failure. Available from: http://clinicaltrials.gov/ct2/show/NCT00421746?term=NCT00421746&rank=1 [Last accessed 29 July 2011]
- Piboserod improves left-ventricular function in patients with symptomatic heart failure. Available from: http://www.docguide.com/piboserod-improves-left-ventricular-function-patients-symptomatic-heart-failure [Last accessed 22 July 2011]
- Product pipeline. Available from: http://www.serodus.com/product_pipeline/ [Last accessed 22 July 2011]
- Löhn M, Plettenburg O, Ivashchenko Y, Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009;54:676-83
- Press releases. Available from: http://en.sanofi.com/press/press_releases/2010/ppc_27174.asp [Last accessed 22 July 2011]
- SAR407899 single-dose in treatment of mild to moderate erectile dysfunction. Available from: http://clinicaltrials.gov/ct2/show/NCT00914277?term=NCT00914277&rank=1 [Last accessed 29 July 2011]
- Oberwittler H, Hirschfeld-Warneken A, Wesch R, Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 2007;47:70-7
- Efficacy and safety study of Ataciguat versus placebo in patients with neuropathic pain. Available from: http://clinicaltrials.gov/ct2/show/NCT00799656?term=NCT00799656&rank=1 [Last accessed 29 July 2011]
- Epstein BJ. Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother 2008;42:1060-9
- Effect of ketoconazole on the pharmacokinetics of Darusentan in healthy subjects. Available from: http://www.aapsj.org/abstracts/AM_2009/AAPS2009-003551.PDF [Last accessed 22 July 2011]
- DORADO - fixed doses of Darusentan as compared to placebo in resistant hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00330369?term=NCT00330369&rank=1 [Last accessed 29 July 2011]
- Second pivotal phase III study of Gilead's Darusentan for resistant hypertension misses primary endpoints. Available from: http://www.gilead.com/pr_1365747 [Last accessed 22 July 2011]
- Gilead sciences announces record fourth quarter and full year 2009 financial results. Available from: http://www.gilead.com/pr_1379225 [Last accessed 22 July 2011]
- Blopress + Actos combination enters PIII. Available from: http://www.accessmylibrary.com/article-1G1-207694031/blopress-actos-combination-enters.html [Last accessed 29 July 2011]
- Company pipeline. Available from: http://www.takeda.com/pdf/usr/default/11_1_37769_2.pdf [Last accessed 22 July 2011]
- Product pipeline. Available from: http://www.takeda.com/pdf/usr/default/11_40972_2.pdf [Last accessed 22 July 2011]
- Johansson S, Cullberg M, Eriksson UG, Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther 2011;49:258-67
- Atrial fibrillation patients not taking vitamin-K antagonist. Available from: http://clinicaltrials.gov/ct2/show/NCT00623779?term=NCT00623779&rank=1 [Last accessed 29 July 2011]
- Prevention of stroke and systemic embolic events in patients with atrial fibrillation. Available from: http://clinicaltrials.gov/ct2/show/NCT00684307?term=NCT00684307&rank=1 [Last accessed 29 July 2011]
- AstraZeneca development pipeline 29 January 2009. Available from: http://www.astrazeneca.se/_mshost9752227/content/resources/gUserfiles/10540506 [Last accessed 22 July 2011]
- Abbott and AstraZeneca announce collaboration to develop and commercialize CRESTOR(R) and next-generation TriCor(R) (ABT-335) fixed-dose combination. Available from: http://www.prnewswire.com/news-releases/abbott-and-astrazeneca-announce-collaboration-to-develop-and-commercialize-crestorr-and-next-generation-tricorr-abt-335-fixed-dose-combination-55793347.html [Last accessed 22 July 2011]
- Martin PD, Dane AL, Schneck DW, An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71
- A year 2, safety extension study of the combination of ABT-335 and statin therapy for subjects with mixed dyslipidemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00491530?term=NCT00491530&rank=1 [Last accessed 29 July 2011]
- Study to evaluate the long-term safety and efficacy of ABT-335, in combination with three different statins in subjects with mixed dyslipidemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00300430?term=NCT00300430&rank=1 [Last accessed 29 July 2011]
- Evaluate safety and efficacy of ABT-335 in combination with Rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood. Available from: http://clinicaltrials.gov/ct2/show/NCT00300482?term=NCT00300482&rank=1 [Last accessed 29 July 2011]
- AstraZeneca and Abbott submit new drug application to the FDA for the approval of CERTRIAD for the treatment of mixed dyslipidemia. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20090604–AstraZeneca-and-Abbott-Submit-New-Drug-Application-to [Last accessed 22 July 2011]
- A FDA report regarding Trilipix indication for coadministration with a statin in May 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM261163.pdf [Last accessed 22 July 2011]
- AstraZeneca and Abbott end license agreement for the development of Certriad. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/AstraZeneca-ends-agreement-with-Abbott-for-Certriad [Last accessed 22 July 2011]
- PeriCor Therapeutics announces closing of licensing agreement for Acadesine with schering-plough corporation. Available from: http://www.pericortherapeutics.com/pdf/070820_PeriCor_SP_press_release_Final.pdf [Last accessed 22 July 2011]
- Dixon R, Gourzis J, McDermott D, AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342-7
- The effect of Acadesine on reducing cardiovascular and cerebrovascular adverse events in coronary artery bypass graft surgery (Study P05633AM1)(TERMINATED) (RED-CABG). Available from: http://clinicaltrials.gov/ct2/show/NCT00872001?term=NCT00872001&rank=1 [Last accessed 29 July 2011]
- Form 10-q. Available from: http://www.sec.gov/Archives/edgar/data/310158/000095012310074336/y83714e10vq.htm [Last accessed 22 July 2011]
- A study to evaluate daily Pravastatin, Fenofibrate or Pravafen in the treatment of combined hyperlipidemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00459745?term=NCT00459745&rank=1 [Last accessed 29 July 2011]
- Financial results for the third quarter of fiscal year 2009. Available from: http://www.shionogi.co.jp/ir_en/materials/detail/con10_02.pdf [Last accessed 22 July 2011]
- 1 half of fiscal 2010 financial results. Available from: http://www.shionogi.co.jp/ir_en/explanatory/pdf/e_p101102.pdf [Last accessed 22 July 2011]
- Meeting highlights from the committee for medicinal products for human use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/01/WC500101076.pdf [Last accessed 22 July 2011]
- Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 2007;97:577-81
- Branca MA. Academia given a helping hand in drug development. Nat Rev Drug Discov 2006;5:177
- Sugiyma Y, Yamashita S. Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev 2011;63:494-502
- Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13:913-16
- Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 2008;7:197-8
- About ‘MetaDrug’. Available from: http://www.genego.com/metadrug.php [Last accessed 22 July 2011]
- Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemp Clin Trials 2010;31:419-22
- Kanavos P. A prospective view on European pharmaceutical research and development - Policy options to reduce fragmentation and increase competitiveness. Pharmacoeconomics 1998;13:181-90